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Background: There remains no consensus on the appropriate application of endovascular abdominal aortic aneurysm
repair (EVAR). Information from administrative databases, industry-sponsored trials, and single institutions has
inherent deficiencies. This study was designed to compare early outcomes of open (OPEN) versus EVAR in a
contemporary (2000 to 2003) large, multicenter prospective cohort.
Methods: Fourteen academic medical centers contributed data to the National Surgical Quality Improvement Program-
Private Sector (NSQIP-PS), which ensures uniform, comprehensive, prospective, and previously validated data entry by
trained, independent nurse reviewers. A battery of clinical and demographic features was assessed with multivariate
analysis for association with the principal study end points of 30-day operative mortality and morbidity.
Results: One thousand forty-two patients underwent elective infrarenal abdominal aortic aneurysm (AAA) repairs: 460
EVAR and 582 OPEN. EVAR patients were older (74 vs 71 years, P < .0001), included more men (84.6% vs 79.6%, P
< .05), and had a higher incidence of chronic obstructive pulmonary disease (25.4% vs 17.9%, P < .01). EVAR resulted
in significantly reduced overall morbidity (24% vs 35%, P < .0001) and hospital stay (4 vs 9 days, P < .0001).
Cardiopulmonary and renal function-related comorbidities had the expected significant impact on mortality for both
procedures at univariate analysis (P < .05). While crude mortality rates between EVAR and OPEN did not differ
significantly (2.8% vs 4.0%) (P  0.32). After multivariate analysis, correlates of operative mortality included OPEN
(odds ratio [OR], 2.44; 95% confidence interval [CI], 1.03 to 5.78; P< .05), advanced age (OR, 1.11; P< .001), history
of angina (OR, 5.54; P < .01), poor functional status (OR, 5.78; P < .001), history of weight loss (OR, 7.42; P < .01),
and preoperative dialysis (OR, 51.4; P < .0001). EVAR also compared favorably to OPEN (OR, 2.14; 95% CI, 1.58 to
2.89; P < .0001) for overall morbidity.
Conclusion: Significant morbidity accompanies AAA repair, even at major academic medical centers. These data strongly
endorse EVAR as the preferred approach in the presence of significant cardiopulmonary or renal comorbidities, or poor
preoperative functional status. ( J Vasc Surg 2005;41:382-9.)Since the advent and progress of the endovascular
repair (EVAR) of infrarenal abdominal aortic aneurysm
(AAA) over the past decade, there remains no consensus on
its appropriate application.1,2 EVAR’s less invasive nature
compared with the conventional open repair (OPEN) in-
tuitively led to its initial application in high-risk patient
populations with AAA. Reports of improved early out-
comes and, in particular, reduced perioperative complica-
tions have fueled growing enthusiasm for such an approach
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382and led some to advocate EVAR in all patients with suitable
anatomy.3,4
A consistent theme of virtually all of the industry-
sponsored trials and single-center reports is the substantial
reduction in overall perioperative morbidity and a more
rapid recovery with EVAR.3,5-9 Alternatively, other reports
raising concerns regarding the durability of EVAR have
curbed enthusiasm and urged caution in its widespread
use.10-12 At present, four ongoing, prospective, random-
ized clinical trials are comparing EVAR versus OPEN, and
preliminary data have recently been published from the
United Kingdom (UK) EVAR trial and the Dutch Ran-
domised Endovascular Aneurysm Management (DREAM )
trial.13,14
In the absence of early data, clinicians have relied
mostly on information from reports of single-institutional
experience, industry-sponsored trials, and administrative
databases, all of which have inherent deficiencies. Most of
these reports concur on the short-term advantages of
EVAR over OPEN in lower perioperative morbidity,
shorter length of stay, and quicker patient recovery; how-
ever, they do not conclusively demonstrate reduced peri-
bstruc
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recent reports from the UK EVAR and DREAM trials do
show an advantage in 30-day mortality with the endovas-
cular approach.13,14
The National Surgical Quality Improvement Program
(NSQIP) was instituted within the Department of Veterans
Affairs (VA) in 1994 as a result of a Congressional mandate
to improve surgical outcomes in the VA system compared
with the national standard.15 It was designed to counteract
some of the deficiencies inherent in retrospective data
analysis. Naturally, the rigor of the NSQIP data collection,
its prospective-nature, and comprehensiveness (complete
30-day follow-up), inclusive of variables not often tracked
in administrative databases, make it an ideal mechanism to
assess and compare complications of surgical procedures.
The methods and efficacy of the NSQIP have been
validated in numerous studies. In 1999, three non-VA
academic medical centers began using NSQIP methods to
test its hypothesis and improve surgical outcomes, thus
forming the NSQIP–Private Sector (PS).16 With funding
from the Agency for Healthcare Research and Quality
(Grant #1U18HS11913-02), the NSQIP–PS has since ex-
panded to the beta sites to include 14 academic medical
centers (Appendix 1).
We used data from the NSQIP-PS to compare the
30-day morbidity and mortality of EVAR versus OPEN
and to examine the preoperative risk factors and comorbidi-
ties that are associated with adverse outcomes of these
Table I. Patient demographics and preoperative variables
Variable
Overall
(n  1042)
Age (mean, yrs) 72.4
Gender (male) 81.8%
Congestive heart failure 2.40%
Angina 3.75%
Myocardial infarction 1.25%
Hypertension 72.2%
Stroke with deficit 6.24%
Stroke with no deficit 4.51%
Transient ischemic attack 5.76%
Diabetes 12.2%
Pack-year smoking (yrs) 41.9
Poor functional status 6.43%
Weight loss 2.78%
Steroid use 5.47%
COPD 21.2%
Ventilator dependent 0.38%
Dialysis 1.25%
Acute renal failure 0.58%
Peripheral vascular disease 8.32%
Rest pain 2.39%
Preoperative laboratory
Hematocrit 39.8%
Prothrombin time (sec) 13.5
Albumin (g/dL) 3.81
Creatinine (mg/dL) 1.32
OPEN, Open surgical repair; EVAR, endovascular repair; COPD, chronic oprocedures in a multicenter, prospective cohort study in thecontemporary era of commercially available aortic en-
dograft devices.
METHODS
Fourteen academic medical centers contribute data to
the NSQIP-PS. At centers that do 140 cases/month, all
eligible general and vascular surgery cases are entered;
however, those institutions with 140 cases/month have
the first 40 consecutive cases entered into the database in
each consecutive 8-day period, beginning with a different
day each period. This is to ensure fair sampling of the types
of cases done on different days of the week. Although not
all cases are captured, this method of random sampling
should lead to a representative sample of surgical cases,
whether one is examining all operations combined or a
specific type of operation.
Data are entered prospectively, reliably, and uniformly
by dedicated, trained, independent clinical nurse reviewers
who undergo periodic quality assessment to ensure the
fidelity of the data collection. The database includes 45
preoperative, 17 intraoperative, and 33 outcome variables.
Patients are followed prospectively to include the 30-day
postoperative period either by letter or telephone survey.
Forty-five days after surgery, each patient’s data entry is
transmitted to the national data coordinating center at the
University of Colorado Health Outcomes Program for
editing and feedback to ensure the quality of the data.
Query was made to the data coordinating center using
OPEN
(n  582)
EVAR
(n  460) P
71.2 74.0 .0001
79.6% 84.6% .04
2.06% 2.83% .42
3.70% 3.79% .94
0.78% 1.79% .16
74.5% 69.6% .10
5.32% 7.39% .17
4.98% 3.91% .41
6.19% 5.22% .51
11.0% 12.7% .42
40.0 44.4 .07
5.67% 7.39% .19
2.92% 2.61% .76
4.30% 6.96% .06
17.9% 25.4% .003
0.34% 0.44% .81
1.20% 1.30% .88
0.69% 0.43% .59
8.58% 8.04% .76
2.92% 1.79% .25
39.8% 39.7% .72
13.5 13.6 .44
3.91 3.71 .10
1.29 1.36 0.30
tive pulmonary disease.common procedural terminology (CPT) codes to obtain
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procedures from January 1, 2000 to October 31, 2003
(Appendix 2). This was categorized by intention-to-treat,
thus patients who started out with an endovascular ap-
proach but were converted to an open procedure were
considered in the EVAR group. The study was approved by
the institutional review board of the Massachusetts General
Hospital.
Outcome measures. The main outcome measures
were 30-day mortality, 30-day morbidity, and length of
postoperative hospital stay for EVAR versus OPEN. Patient
demographics and preoperative comorbidities were also
compared and analyzed in a risk-adjusted model to predict
outcome. Overall morbidity was defined as the presence of
one or more of the adverse events, listed by systems with
definitions in Appendix 3 (online only).
Definitions of preoperative data variables. Of the
45 preoperative variables included in the NSQIP, some had
very few or no occurrences and were excluded from analy-
sis. In addition, preoperative variables that might duplicate
each other in assessing risks were narrowed. Historically or
traditionally regarded risk factors such as cardiac, pulmo-
nary, and renal risk factors were included. The following
independent preoperative variables were defined as such:
● congestive heart failure within 30 days before surgery,
● history of angina within 1 month before surgery,
● myocardial infarction within 6 months before surgery,
● hypertension requiring medications,
● stroke, with and without neurologic deficit;
● diabetes mellitus treated with oral hypoglycemic drugs
or insulin,
● poor functional health status with partial or total de-
pendency for activities of daily living,
● weight loss 10% body weight within 6 months of
surgery,
● steroid medication for a chronic condition,
● ventilator dependent within 48 hours of surgery,
● acute renal failure with rapidly increasing azotemia and
rapidly rising levels of serum creatinine 3 mg/dL,
● peripheral vascular disease with history of revascular-
ization or amputation,
● ischemic rest pain and/or gangrene.
Statistical analysis. Chi-square analysis was used to
compare categorical variables and the Student t-test was
used for continuous variables. Univariate analysis was per-
formed between the main outcome measure of mortality or
morbidity and the 20 independent preoperative variables
listed in Table I. The significant variables (P  .05) were
then considered in a multivariate logistic regression model
that was used to identify independent predictors of adverse
outcomes. Odds ratios (ORs) were reported with 95%
confidence intervals. All statistical analyses were performed
using the Statistical Analysis System (SAS) version 8.0
software (SAS Institute, Cary, NC).RESULTS
Patient demographics and preoperative risk factors.
From January 1, 2000 to October 31, 2003, 1042 patients
randomly sampled underwent elective infrarenal AAA re-
pairs in centers participating in the NSQIP–PS. The distri-
bution of EVAR versus OPEN among the participating
centers is listed in Appendix 4 (online only). Of those, 582
(56%) had an open repair and 460 (44%) had an endovas-
cular repair, the selection of which was surgeon preference.
The average age was 72 years, and 82% of the patients were
men. Compared with OPEN, EVAR patients were older
(74 vs 71 years, P .0001) and included a higher percent-
age of men (84.6% vs 79.6%, P  .04). There was no
significant difference in comorbidities or other preoperative
risk factors between EVAR and OPEN, with the exception
that more patients with chronic obstructive pulmonary
disease (COPD) were in the EVAR group than in OPEN
group (25.4% vs 17.9%, P  .003) (Table I).
Operative details and principal outcomes. Details of
the operative procedure, principal outcomes, and univari-
ate analysis of factors examined for association with opera-
tive mortality are summarized in Tables II through IV.
Nine (2.0%) of the 460 patients who started with an endo-
vascular approach were converted to an open procedure
with one death for an 11% conversion mortality. Although
the crude or unadjusted 30-day mortality rate between
EVAR and OPEN did not differ (2.8% vs 4.0%, P  .32),
multivariate logistic regression analysis revealed a mortality
OR of 2.44 (95% confidence interval [CI], 1.03 to 5.78)
for OPEN, which was statistically significant (P  .05).
The other significant multivariate correlates for mortality
included advanced age, history of angina, poor functional
status, history of weight loss, and preoperative dialysis
dependent (Table V).
EVAR resulted in a significantly lower 30-day overall
morbidity rate of 24% compared with 35% for OPEN (P 
.0001). This lower morbidity rate was also reflected in a
much shorter mean postoperative length of stay in the
Table II. Operative details
Variable Overall OPEN EVAR P
General anesthesia 84.4% 97.3% 68.0% .0001
Unit RBC transfused 1.55 2.27 0.64 .0001
Length of operation (hrs) 3.61 3.82 3.35 .0001
OPEN, Open surgical repair; EVAR, endovascular repair; RBC, red blood
cells.
Table III. Principal Outcomes
Overall OPEN EVAR P
30-day mortality 3.45% 3.95% 2.83% 0.32
30-day morbidity 30% 35% 24% .0001
Postop stay (days) 7.1 9.3 4.4 .0001
OPEN, Open surgical repair; EVAR, endovascular repair.EVAR group of 4 days, in contrast to 9 days for the OPEN
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EVAR group was only 2 days compared to 7 days for
OPEN.
Similarly, univariate analysis was carried out with mor-
bidity as the main outcome measure (Table VI). At multi-
variate analysis, the treatment type, OPEN, remained a
significant predictor of adverse outcomes (OR, 2.14; 95%
CI, 1.58 to 2.89; P  .0001). The other variables lost their
significance with the exception of patient age, history of
congestive heart failure, and history of ischemic rest pain
(Table VII).
Postoperative complications. EVAR significantly re-
duced postoperative complications as seen in the overall
30-day morbidity rates and in the logistic regression mod-
els. Pulmonary complications were significantly less in the
Table IV. Univariate analysis of preoperative variables
and mortality
Variable
Odds
ratio 95% CI P
OPEN 1.42 0.71-2.82 .33
Age 1.08 1.03-1.13 .001
Gender (male) 1.82 0.63-5.19 .27
Congestive heart failure 4.07 1.16-14.3 .03
Angina 4.00 1.33-12.1 .01
Myocardial infarction 6.13 1.29-29.2 .02
Hypertension 0.84 0.39-1.80 .66
Stroke with deficit 0.88 0.21-3.75 .86
Stroke with no deficit 1.26 0.29-5.39 .76
Transient ischemic attack 1.51 0.45-5.09 .50
Diabetes 1.30 0.65-2.61 .47
Pack-year smoking 1.00 0.99-1.01 .31
Poor functional status 5.78 3.04-11.0 .0001
Weight loss 4.91 1.61-14.9 .005
Steroid use 2.96 1.10-7.90 .03
COPD 1.67 0.81-3.44 .17
Ventilator dependent 9.55 0.97-94.2 .053
Dialysis 28.5 9.05-90.1 .0001
Acute renal failure 14.7 2.61-83.2 .002
Peripheral vascular disease 2.11 0.79-5.64 .14
Rest pain 1.33 0.17-10.2 .78
OPEN, Open surgical repair; COPD, chronic obstructive pulmonary disease
Table V. Independent predictors of death at multivariate
analysis
Variable
Odds
ratio 95% CI P
OPEN 2.44 1.03-5.78 .04
Age 1.11 1.05-1.17 .0004
Congestive heart failure 1.02 0.12-8.61 .98
Angina 5.54 1.57-19.6 .008
Myocardial infarction 4.32 0.47-39.9 .20
Poor functional status 5.78 2.24-14.9 .0003
Weight loss 7.42 1.97-28.0 .003
Steroid use 3.04 0.93-9.95 .07
Dialysis 51.4 10.0-264 .0001
Acute renal failure 8.68 0.75-100 .08
OPEN, Open surgical repair.EVAR group compared with OPEN (6.3% vs 18.2%, P .0001). Cardiac and renal complications were also lower
with EVAR, but they failed to reach statistical significance.
OPEN resulted in a significantly higher rate of postopera-
tive systemic sepsis (4.6% vs 1.7%, P  .001), more post-
operative bleeding requiring 4 units of red blood cells
(9.6% vs 5.0%, P  .005), and prolonged ileus 5 days
(0.9% vs 0%, P  .05). However, the rate of graft throm-
bosis was higher in the EVAR group compared with OPEN
(2.0% vs 0.3%, P  .01) as was the rate of deep wound
infection (2.2% vs 0.5%, P  .02) (Table VIII).
DISCUSSION
Despite more than a decade of experience with endo-
vascular therapy of AAA, conclusive data comparing endo-
vascular with open repair of AAA are still not available;
Table VI. Univariate analysis of preoperative variables
and major morbidity
Variable
Odds
ratio 95% CI P
OPEN 1.76 1.34-2.32 .0001
Age 1.04 1.02-1.06 .0001
Gender (male) 0.57 0.41-0.79 .0007
Congestive heart failure 2.56 1.16-5.68 .02
Angina 1.97 1.01-3.86 .05
Myocardial infarction 2.43 0.78-7.59 .13
Hypertension 1.31 0.96-1.81 .09
Stroke with deficit 1.11 0.65-1.90 .71
Stroke with no deficit 1.09 0.58-2.04 .80
Transient ischemic attack 1.71 1.00-2.90 .05
Diabetes 1.33 0.98-1.81 .07
Pack-year smoking 1.00 1.00-1.00 .85
Poor functional status 1.78 1.13-2.80 .01
Weight loss 1.22 0.56-2.66 .61
Steroid use 1.87 1.09-3.22 .02
COPD 1.42 1.03-1.94 .03
Ventilator dependent 6.98 0.72-67.4 .09
Dialysis 1.45 0.47-4.47 .52
Acute renal failure 4.66 0.85-25.6 .08
Peripheral vascular disease 1.32 0.82-2.14 .26
Rest pain 2.68 1.17-6.15 .02
OPEN, Open surgical repair;COPD, chronic obstructive pulmonary disease.
Table VII. Independent predictors of major morbidity
at multivariate analysis
Variable
Odds
ratio 95% CI P
OPEN 2.14 1.58-2.89 .0001
Age 1.05 1.03-1.07 .0001
Gender (male) 0.75 0.52-1.07 0.11
Congestive heart failure 3.04 1.22-7.55 0.02
Angina 1.84 0.89-3.81 0.10
Transient ischemic attack 1.30 0.72-2.35 0.38
Poor functional status 1.22 0.68-2.19 0.51
Steroid use 1.77 0.97-3.21 0.06
COPD 1.32 0.91-1.91 0.15
Rest pain 3.10 1.24-7.79 0.02
OPEN, Open surgical repair;COPD, chronic obstructive pulmonary disease.however, early results from two of the randomized clinical
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available are data from single-institution reports, industry-
sponsored clinical trials, and administrative databases with
all of their inherent flaws.6-9, 17-21 Many reports on periop-
erative outcomes are subject to criticism because of small
sample size and the relatively low incidence of any particular
end point.22,23 Large administrative database studies have
the advantage of large sample size; however, the clinical data
end points lack complete 30-day postoperative follow-up, and
the precision and depth of the variables examined for associa-
tion with end points are of questionable veracity.18
The NSQIP provides a unique database which over-
comes many of these limitations; data are entered prospec-
tively, uniformly, and accurately by clinical nurse reviewers
who are independent and trained using methods that have
been validated. The NSQIP methods have had docu-
mented success in the VA system, providing valuable feed-
back such as risk-adjusted outcomes to each individual
participating hospital and in the process, reducing the
overall morbidity and mortality rates within the entire VA
system.24 We used this unique database in our study to
explore the differences in the 30-day outcomes between
EVAR and OPEN in the contemporary era of commercially
available endografts and develop a risk-adjusted model to
Table VIII. Specific organ or system-related postoperativ
Overall
Cardiac 2.3%
Cardiac arrest 1.3%
Myocardial infarction 1.6%
Other major cardiac 4.7%
Pulmonary 13.0%
Failure to wean 48 hrs 6.1%
Pneumonia 5.5%
Reintubation 6.1%
Pulmonary embolism 0.5%
Other major pulmonary 3.4%
Renal 3.6%
Acute renal failure 1.6%
Renal insufficiency 2.2%
Neurologic 2.3%
Stroke 0.9%
Peripheral nerve injury 0.5%
Other major neuro 1.3%
Infectious 6.9%
Systemic sepsis 3.4%
Urinary tract infection 5.1%
Wound 5.6%
Superficial infection 2.4%
Deep wound infection 1.3%
Wound dehiscence 1.3%
Graft failure 1.1%
Hematologic 8.1%
Postop bleed 4 units 7.6%
Deep venous thrombosis 0.8%
Miscellaneous
Prolonged ileus 5 days 0.5%
Other urinary 1.3%
Other complications 7.6%predict adverse outcomes.The perioperative mortality rate for open AAA repair
ranges from 1.1% to 5.8% in most institutional and multi-
center trials, and this rate is even higher in large population-
based studies, ranging from 3.5% to 8.4%.19-21,25-29 The
30-day mortality rate of 4.0% for OPEN in our study is
comparable to most studies cited, but was not significantly
different from the 30-day mortality rate of 2.8% for EVAR.
All of the industry-sponsored trials have reported mor-
tality rates with EVAR, ranging from 0.5% to 2.6% (aver-
age, 1.64%).6-8,30 However, the OPEN arm in these stud-
ies had an even lower mortality of 0.93%, with no statistical
difference. Larger studies had comparable EVAR mortality
rates to that of our study, such as the EUROSTAR registry
with a 3.2% mortality rate and a more recent New York state
population-based study with an EVAR mortality of 3.1% in
the year 2000 decreasing to 1.1% and 0.8% for the subse-
quent 2 years, respectively.20, 31
Similar to the findings reported here, Lee et al18 re-
cently reported lower mortality with EVAR versus OPEN
(1.3% vs 3.8%, P  .0001) in a study with a large sample
size using the National Inpatient Sample database. Even
more recently, Greenhalgh at al13 published the 30-day
mortality rates from the UK randomized clinical trial com-
paring EVAR versus OPEN that showed an advantage with
plications (30-day)
OPEN EVAR P
3.1% 1.3% .06
1.9% 0.4% .04
2.2% 0.9% .08
5.5% 3.7% .17
18.2% 6.3% .0001
8.8% 2.6% .0001
7.9% 2.4% .0001
7.6% 4.4% .03
0.5% 0.4% .85
4.5% 2.0% .03
4.5% 2.4% .07
2.2% 0.9% .08
2.2% 2.2% .95
2.6% 2.0% .51
1.2% 0.4% .18
0.3% 0.7% .47
1.0% 1.7% .32
8.6% 4.8% .02
4.6% 1.7% .001
5.8% 4.1% .21
5.5% 5.7% .91
2.6% 2.2% .67
0.5% 2.2% .02
1.7% 0.9% .24
0.3% 2.0% .01
10.0% 5.7% .01
9.6% 5.0% .005
0.7% 0.9% .74
0.9% 0 .05
1.2% 1.5% .66
8.6% 6.3% .17e comEVAR of 1.7% versus 4.7% (OR, 0.35; 95% CI, 0.16 to
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OPEN 30-day mortality of 4.6% compared with 1.2% for
the EVAR group with a risk ratio of 3.9 (95% CI, 0.9 to
32.9).14
All of the phase II device clinical trials failed to show a
difference in mortality between the two procedure types
with the exception of the Cook Zenith Phase II trial as
reported by Greenberg.6-9,30,32 Thus, it is reasonable to
conclude that the industry-sponsored trials were insuffi-
ciently powered to detect differences in mortality between
EVAR and OPEN.
Albeit the lack of statistical difference in the crude or
unadjusted 30-day mortality rates between OPEN and
EVAR, logistic regression analysis demonstrated a higher
risk of death for those undergoing OPEN compared with
EVAR (OR, 2.44; P  .05). Thus, after adjustment for
preoperative risk factors, OPEN resulted in a significantly
higher mortality. This is certainly consistent with the recent
reports from the UK EVAR trial that showed a two thirds
reduction in the 30-day mortality with EVAR compared
with OPEN, as well as the DREAM trial in which there was
nearly a fourfold increased risk of mortality for OPEN
versus EVAR.13,14
As noted in our study, postoperative pulmonary com-
plications were by far the most common organ-specific
source of morbidity. Assuming that the surgeons in these
14 academic medical centers were more likely to recom-
mend EVAR to poor-risk patients (certainly this is our
practice), the risk factor profile &#x2036;balancing is
likely explained by the fact that many patients are simply
not anatomic candidates for EVAR. As device evolution
proceeds, the percentage of patients potentially treatable
with EVAR is likely to increase.
These data clearly suggest that EVAR is the procedure
of choice in high-risk patients, acknowledging that this
characterization is a relative term. An important compo-
nent of our data are elements such as steroid use and poor
functional status (Table IV) that are rarely considered or
even retrievable in many administrative database-type stud-
ies and are difficult to quantify. Although surgeons were
likely to have considered these composite elements in daily
clinical decision-making, the power of our sample size
provides the ominous prognostic implications of variables
such as poor functional status. Thus, a reasonable conclu-
sion from this study is that elective AAA repair should rarely
be offered to dialysis-dependent patients, who have a 50-
fold increased procedural mortality. Others have empha-
sized the importance of renal failure in predicting mortality
after open AAA repair.28,33,34 These data should assist
vascular surgeons in clinical decision-making. Elderly and
poor-risk patients (Table V) should be offered EVAR.
Despite the previous discussion on periprocedural mor-
tality, it is uncommon (3.5% in our study); surgeons and
their patients are more likely to be affected by overall
morbidity and the investment in recovery from surgery.
There is general consensus and ample documentation that
the less invasive EVAR results in fewer complications than
OPEN. Our study details an overall 24% morbidity rate forEVAR, higher than the average of 15% reported in the
literature.2,3,6,7,18 This is likely due to the strict reporting
standards of the NSQIP. Despite this, overall morbidity for
EVAR is significantly lower than that seen with OPEN
patients, who have a twofold increased risk of morbidity
after multivariate analysis. Not surprisingly, elderly patients
and those with concomitant advanced arterial insufficiency
are at risk for significant problems in recovery. While the
former variable has been repetitively emphasized, few re-
ports document the inherently logical implication of severe
leg ischemia.
The predominant postoperative complication overall is
pulmonary in nature, with a rate of 18% in OPEN com-
pared with 6% in EVAR patients (P  .0001). This is
hardly surprising, given the procedural, anesthetic, and
blood loss difference in the two procedures. Other reports
revealed similar pulmonary complication rates of 16% to
20% for OPEN compared with 2% to 3% for EVAR.4,19 In
our study, there was no real difference in cardiac, renal, or
wound complication rates, although as already discussed,
baseline renal insufficiency is of great importance in patient
selection. OPEN did result in a higher rate of postoperative
bleeding and systemic sepsis that has also been well docu-
mented. The less invasive nature of EVAR and the lower
complication rates, not unexpectedly, are translated into a
significantly shorter hospital stay, also consistent with other
reports.18,35
Graft limb thrombosis, though uncommon in this co-
hort, was a significant issue in EVAR compared with
OPEN. Certainly, this was an important issue in our expe-
rience with earlier graft constructs. Perhaps this point is
influenced in a major way by the expertise of the OPEN
surgeons in this cohort, whose graft occlusion rate was but
0.3%. Our report cannot address the issue of late re-inter-
ventions. Whether this higher rate of graft limb thrombosis
with EVAR translated to a higher re-intervention rate is
unknown, although that would certainly concur with the
literature reports of increased late re-interventions with
EVAR compared with OPEN.36
Limitations of this study are that late outcomes (30-
day postoperative) are not available; therefore, conclusions
about the long-term effectiveness and durability of EVAR
cannot be made. The NSQIP database is not set up to
include all of the nuances particular to a procedure, and so
aortic anatomic data on patients undergoing AAA repair are
not captured. Whether all OPEN patients were anatomic
candidates for EVAR is not known. Certainly, this poses a
weakness in the study. In addition, this database also lacks
device-specific information, although the study was con-
ducted in the period after United States Food and Drug
Administration approval of several of the endograft devices.
CONCLUSION
The NSQIP provides a unique database to study and
compare early outcomes of vascular procedures, including
endovascular versus open AAA repair. Significant morbidity
accompanies AAA repair, even at major academic medical
centers. In a risk-adjustment analysis, OPEN patients had
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tality. The debates about durability considerations of
EVAR versus OPEN are not addressed in this study, but
these data strongly endorse EVAR as the preferred ap-
proach, particularly in the presence of significant anteced-
ent comorbidities and poor preoperative functional status.
EVAR results in lower postoperative complications and
decreased length of stay. OPEN is a significant predictor of
morbidity and mortality.
APPENDIX I. The 14 participating academic medical
centers in the NSQIP–PS
Brigham & Women’s Hospital
Columbia University
Cornell University
Emory University*
Massachusetts General Hospital
Saint Louis University
University of California, San Francisco
University of Florida
University of Kentucky*
University of Maryland
University of Michigan*
University of Utah
University of Virginia
Washington University
NSQIP-PS, National Surgical Quality Improvement Program-Private Sector
*Pilot members of the NSQIP–PS
APPENDIX II. Common procedural terminology
(CPT) codes used
Operation CPT codes
EVAR 34800, 34802, 34804, 34830,
34831, 34832
OPEN 35081, 35102
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Appendix 3 (online only).
NSQIP definitions of postoperative complications
Cardiac
Cardiac arrest Absence of cardiac rhythm or VFib
requiring CPR
Myocardial infarction New transmural MI within 30
days of surgery
Pulmonary
Failure to wean 48 hrs On ventilator 48 hours
postoperative
Pneumonia CDC definition of pneumonia
Reintubation Unplanned intubation after
surgery
Pulmonary embolism High probability VQ, positive
pulm. angio or CTA
Renal
Acute renal failure Requiring dialysis or
ultrafiltration postop only
Renal insufficiency Cr rise 2 mg/dL from preop,
but no dialysis required
Neurologic
Stroke As stated
Peripheral nerve injury Peripheral motor or sensory
nerve damage
Infectious
Systemic sepsis At least two of the following:
Temp 38°C, 36 °C; HR
90; RR 20 or PCO2 32;
WBC 12, 4
Urinary tract infection CDC definition
Wound
Superficial infection CDC definition
Deep wound infection CDC definition
Wound dehiscence Disruption of fascial layer
Graft failure Mechanical failure of vascular
graft
Hematologic
Postop. bleed 4 units Within 72 hours postoperative
Deep venous
thrombosis
As stated
Miscellaneous
Prolonged ileus 5 days Mechanical or functional
obstruction 5 days
Other complications
NSQIP, National Surgical Quality Improvement Program; Vfib, ventricular
fibrillation; MI, myocardial infarction; CDC, Centers for Disease Control;
CTA, computed tomographic angiography; Cr, creatinine; HR, heart rate;
RR, respiration rate; WBC, white blood cells.
Appendix 4 (online only).
Case distribution among the participating sites
Site OPEN EVAR
1 104 88
2 44 18
3 63 4
4 46 68
5 38 6
6 5 24
7 38 25
8 38 13
9 90 19
10 4 7
11 18 46
12 14 45
13 19 22
14 60 72
Other 1 3
Total 582 460
OPEN, Open surgical repair; EVAR, endovascular repair
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